Effect of simvastatin on hemostasis in <font color="red">patients_3</font> <font color="red">with_3</font> <font color="red">isolated_3</font> <font color="red">hypertriglyceridemia_3</font> <font color="red">._3</font> 
<br>
<br> BACKGROUNDS / AIMS Elevated triglyceride levels seem to predispose to the earlier development and accelerated progression of coronary artery disease . In our study , we assessed for the first time whether simvastatin treatment affects coagulation and fibrinolysis in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">isolated_2</font> <font color="red">hypertriglyceridemia_2</font> <font color="red">._2</font> 
<br> METHODS The <font color="red">study_1</font> <font color="red">included_1</font> <font color="red">39_5</font> <font color="red">patients_5</font> <font color="red">with_5</font> <font color="red">elevated_5</font> <font color="red">triglyceride_5</font> <font color="red">levels_5</font> <font color="red">and_5</font> <font color="red">peripheral_5</font> <font color="red">artery_5</font> <font color="red">sclerosis_5</font> <font color="red">,_5</font> <font color="red">treated_2</font> <font color="red">for_2</font> <font color="red">90_2</font> <font color="red">days_2</font> <font color="red">with_2</font> <font color="red">either_2</font> <font color="red">simvastatin_2</font> <font color="red">(_2</font> <font color="red">40_2</font> <font color="red">mg_2</font> <font color="red">daily_2</font> <font color="red">)_2</font> <font color="red">or_2</font> <font color="red">placebo_2</font> <font color="red">._1</font> Plasma lipids , glucose homeostasis markers and hemostasic variables were assessed at baseline and after treatment . 
<br> RESULTS Simvastatin , but not placebo , administered to these patients reduced plasma levels / activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g / l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0% , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng / ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times . 
<br> CONCLUSION Our results suggest that statin treatment produces a multidirectional effect on coagulation and fibrinolysis in <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">isolated_1</font> <font color="red">hypertriglyceridemia_1</font> and that this treatment may bring some benefits to <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">elevated_1</font> <font color="red">triglyceride_1</font> <font color="red">levels_1</font> <font color="red">._1</font>